Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10577323 | 1.00 | TRPA1 (0.48) | TRPA1CYP1A2EPHX1SRRALPI | |
| SCHEMBL15517655 | 0.87 | SRR (0.50) | CYP1A2SRRPTGS1TAAR1ALDH1A1 | |
| SCHEMBL10187479 | 0.87 | SRR (0.50) | CYP1A2SRRPTGS1TAAR1ALDH1A1 | |
| SCHEMBL28633253 | 0.87 | SRR (0.50) | CYP1A2SRRPTGS1TAAR1ALDH1A1 | |
| SCHEMBL1833635 | 0.85 | TRPA1 (0.55) | TRPA1CYP1A2EPHX1SRRALPI | |
| SCHEMBL11824337 | 0.82 | SLC6A4 (0.54) | TRPA1MAOASLC6A4POLBTRPV1 | |
| SCHEMBL10187484 | 0.82 | PPARG (0.54) | — | |
| SCHEMBL1552840 | 0.82 | PPARG (0.58) | CYP1A2PTGS1SLC6A2MAOASLC6A3 | |
| SCHEMBL1552843 | 0.82 | PPARG (0.58) | CYP1A2PTGS1SLC6A2MAOASLC6A3 | |
| Ammonia Solution, Strong SCHEMBL29021310 | 0.82 | TRPA1 (0.53) | TRPA1CYP1A2EPHX1SRRALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2023-01-17 | — | — | US | disclosed |
| EP-2964611-B1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-05-06 | — | — | US | disclosed |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-09 | — | — | US | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-06-20 | — | — | US | disclosed |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2018-04-05 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-20080220487-A1 | Molecular design of thermostable alcohol dehydrogenase for synthesis for chiral aromatic alcohols | THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| US-20080220487-A1 | Molecular design of thermostable alcohol dehydrogenase for synthesis for chiral aromatic alcohols | THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| US-20080220487-A1 | Molecular design of thermostable alcohol dehydrogenase for synthesis for chiral aromatic alcohols | THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| US-20080207853-A1 | Precatalysts useful in polyolefin polymerization reactions | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2008-08-28 | — | — | US | disclosed |
| WO-2008013949-A2 | MOLECULAR DESIGN OF THERMOSTABLE ALCOHOL DEHYDROGENASE FOR SYNTHESIS FOR CHIRAL AROMATIC ALCOHOLS | MICHIGAN STATE UNIVERSITY (US) | 2008-01-31 | — | — | WO | disclosed |
| US-5011992-A | Antiemetics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4820715-A | TREATING NAUSEA AND GASTRIC DISORDERS | BRISTOL-MYERS COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4808624-A | ANTIEMETICS | BRISTOL-MYERS COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-3985808-A | SECONDARY ALCOHOLS OR HALOHYDRINS REACTED WITH A HALOGEN | LEVER BROTHERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3944568-A | Process for the preparation of selectively halogenated ketals | LEVER BROTHERS COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185424-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-10590074-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-20210130288-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-20080220487-A1 | Molecular design of thermostable alcohol dehydrogenase for synthesis for chiral aromatic alcohols | ADH5, ADH1C, ADH1A | TRPA1 2952/4885CYP1A2 51/4885EPHX1 269/4885 |
| US-11555013-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-20180093947-A1 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-10913711-B2 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | SLC6A2, SLC6A4, SLC6A3 | TRPA1 3412/4885CYP1A2 580/4885EPHX1 2980/4885 |
| US-20080207853-A1 | Precatalysts useful in polyolefin polymerization reactions | PPOX, PORCN, PTGES | TRPA1 2170/4885CYP1A2 634/4885EPHX1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.